Imcyse raises 35 mln euros

Imcyse said June 18 that it raised 35 million euros ($31.6 million) in a Series B round led by LSP together with Belgian investors including Epimède, the Société Régionale d'Investissement de Wallonie, and the Société Fédérale de Participations et d'Investissement. Existing shareholders (Biogenosis, Noshaq, KU Leuven) also participated in the round. Imcyse, of Liege, Belgium, develops active specific immunotherapies for the treatment and prevention of severe chronic diseases.

North AmericaUSBriefs